HRTX Material Contracts | HERON THERAPEUTICS, INC. /DE/

HERON THERAPEUTICS, INC. /DE/ Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

2026-08-10: Form 10-Q; Exhibit 10.3; Description Waiver, Consent, and Fourth Amendment to the Working Capital Facility Agreement, dated August 7, 2026, by and between Heron Therapeutics, Inc. and Hercules Capital, Inc., as administrative agent, collateral agent, and lender.
2026-08-10: Form 10-Q; Exhibit 10.2; Description Amendment No. 2 to Framework Agreement, dated July 20, 2026, by and between Heron Therapeutics, Inc. and Patheon Austria GmbH & Co KG.
2026-08-10: Form 10-Q; Exhibit 10.1; Description Amendment No. 1 to Framework Agreement, dated November 13, 2025, by and between Heron Therapeutics, Inc. and Patheon Austria GmbH & Co KG.
2026-04-06: Form 8-K; Exhibit 10.4; Description Amended and Restated Management Retention Agreement, dated April 3, 2026, by and between Heron Therapeutics, Inc. and Mark Hensley..

Filed	Form	Exhibit	Description
2026-08-10	10-Q	10.3	Waiver, Consent, and Fourth Amendment to the Working Capital Facility Agreement, dated August 7, 2026, by and between Heron Therapeutics, Inc. and Hercules Capital, Inc., as administrative agent, collateral agent, and lender
2026-08-10	10-Q	10.2	Amendment No. 2 to Framework Agreement, dated July 20, 2026, by and between Heron Therapeutics, Inc. and Patheon Austria GmbH & Co KG
2026-08-10	10-Q	10.1	Amendment No. 1 to Framework Agreement, dated November 13, 2025, by and between Heron Therapeutics, Inc. and Patheon Austria GmbH & Co KG
2026-04-06	8-K	10.4	Amended and Restated Management Retention Agreement, dated April 3, 2026, by and between Heron Therapeutics, Inc. and Mark Hensley.
2026-04-06	8-K	10.3	Amended and Restated Management Retention Agreement, dated April 3, 2026, by and between Heron Therapeutics, Inc. and Ira Duarte.
2026-04-06	8-K	10.2	Amended and Restated Management Retention Agreement, dated April 3, 2026, by and between Heron Therapeutics, Inc. and Bill Forbes.
2026-04-06	8-K	10.1	Amended and Restated Executive Employment Agreement, dated April 3, 2026, by and between Heron Therapeutics, Inc. and Craig Collard.
2026-02-26	10-K	10.26	Amendment No. 7 to Co-Promotion Agreement, dated as of August 15, 2025, by and between the Company and Crosslink Network, LLC
2026-02-26	10-K	10.18	Third Amendment to Working Capital Facility Agreement, dated January 30, 2026, by and between Heron Therapeutics, Inc. and Hercules Capital, Inc., as administrative agent, collateral agent, and lender
2026-02-26	10-K	10.6	Agreement of Sublease, dated as of September 23, 2024 by and between the Company and Crown Castle USA, Inc.
2026-02-26	10-K	10.5	Form of Indemnification Agreement
2026-02-26	10-K	10.4	Form of 2007 Equity Incentive Plan Restricted Stock Unit Agreement
2026-02-26	10-K	10.3	Form of 2007 Equity Incentive Plan Stock Option Agreement
2025-11-04	10-Q	10.8	Amendment No. 6 to Co-Promotion Agreement, dated as of August 15, 2025, by and between the Company and Crosslink Network, LLC
2025-11-04	10-Q	10.7	Office Lease Agreement, dated August 22, 2025, by and between Heron Therapeutics, Inc. and USEF HCG Fenton LLC
2025-11-04	10-Q	10.1	Form of Convertible Senior Unsecured Promissory Note due 2031 (included in Exhibit 10.6)
2025-08-12	8-K	10.5	Securities Purchase Agreement, dated August 8, 2025, by and among Heron Therapeutics, Inc. and the purchasers party thereto.
2025-08-12	8-K	10.4	Note Purchase Agreement, dated August 8, 2025, by and among Heron Therapeutics, Inc., the purchasers party from time to time thereto and Rubric Capital Management LP.
2025-08-12	8-K	10.3	Exchange Agreement, dated August 8, 2025, by and among Heron Therapeutics, Inc. and the holders party thereto.
2025-08-12	8-K	10.2	Second Amendment to Working Capital Facility Agreement, dated August 8, 2025, by and among Heron Therapeutics, Inc., Hercules Capital, Inc., as administrative agent and collateral agent, and the lenders party thereto.
2025-08-12	8-K	10.1	Cooperation Agreement, dated August 8, 2025, by and among Heron Therapeutics, Inc. and Rubric Capital Management LP.
2025-08-08	10-Q	10.4	Amendment No. 5 to Co-Promotion Agreement, dated as of January 5, 2024, by and between the Company and CrossLink Network, LLC
2025-08-08	10-Q	10.3	Management Retention Agreement, dated April 28, 2025, by and between the Company and Mark Hensley
2025-08-08	10-Q	10.2	Amendment No. 4 to Co-Promotion Agreement, dated as of January 5, 2024, by and between the Company and CrossLink Network, LLC
2025-08-08	10-Q	10.1	Amendment No. 3 to Co-Promotion Agreement, dated as of January 5, 2024, by and between the Company and CrossLink Network, LLC
2025-02-27	10-K	10.6	Agreement of Sublease, dated as of September 23, 2024 by and between the Company and Crown Castle USA, Inc.
2025-02-27	10-K	10.5	Form of Indemnification Agreement
2025-02-27	10-K	10.4	Form of 2007 Equity Incentive Plan Restricted Stock Unit Agreement
2025-02-27	10-K	10.3	Form of 2007 Equity Incentive Plan Stock Option Agreement
2025-02-20	8-K	10.1	First Amendment to Working Capital Facility Agreement, dated as of February 13, 2025, by and among the Company, the several banks and other financial institutions or entities from time to time party thereto, and Hercules Capital, Inc.
2024-11-12	10-Q	10.2	Amendment No. 2 to Co-Promotion Agreement, dated as of January 5, 2024, by and between the Company and Crosslink Network, LLC
2024-11-12	10-Q	10.1	Amendment No. 1 to Co-Promotion Agreement, dated as of January 5, 2024, by and between the Company and Crosslink Network, LLC
2024-05-07	10-Q	10.1	Co-Promotion Agreement, dated as of January 5, 2024, by and between the Company and Crosslink Network, LLC
2023-08-14	10-Q	10.10	Working Capital Facility Agreement, dated August 9, 2023, by and among the Company, the several banks and other financial institutions or entities from time to time party thereto, and Hercules, Capital, Inc.
2023-08-14	10-Q	10.4	Management Retention Agreement, dated June 16, 2023, by and between the Company and Ira Duarte
2023-08-14	10-Q	10.3	Management Retention Agreement, dated June 6, 2023, by and between the Company and William Forbes
2023-08-14	10-Q	10.1	Executive Employment Agreement, dated April 3, 2023, by and between the Company and Craig Collard
2023-07-24	8-K	10.2	Amendment to Executive Employment Agreement, dated May 5, 2023, by and between the Company and David Szekeres.
2023-07-24	8-K	10.1	Securities Purchase Agreement, dated July 21, 2023, by and among the Company and the Purchasers signatory thereto.
2023-02-22	8-K	10.1	Cooperation Agreement, dated February 21, 2023, by and among Heron Therapeutics, Inc., Rubric Capital Management LP, the persons and entities listed on Schedule A thereto, Velan Capital Investment Management LP, and the persons and entities listed on Schedule B thereto
2022-08-10	8-K	10.1	Securities Purchase Agreement, dated August 8, 2022, by and among the Company and the Purchasers signatory thereto
2022-08-09	10-Q	10.3	Amendment to Management Retention Agreement, dated January 14, 2020, as amended on August 8, 2022, by and between the Company and Lisa Peraza
2022-08-09	10-Q	10.2	Amendment to Executive Employment Agreement, dated July 15, 2019, as amended on August 8, 2022, by and between the Company and John Poyhonen
2022-08-09	10-Q	10.1	Executive Employment Agreement, dated March 17, 2016, by and between the Company and David Szekeres
2021-11-03	10-Q	10.1	Fourth Amendment to Lease, dated October 13, 2021, by and between the Company and ARE-SD Region No. 61, LLC
2021-05-25	8-K	10.1	Note Purchase Agreement, dated as of May 24, 2021, by and among Heron Therapeutics, Inc. and funds affiliated with Baker Bros. Advisors LP
2019-12-20	8-K	10.1	Third Amendment to Lease, dated December 19, 2019
2019-08-05	10-Q	10.1	Executive Employment Agreement, dated July 15, 2019, by and between the Company and John Poyhonen
2018-05-10	10-Q	10.1	Second Amendment to Lease, dated May 8, 2018, by and between Heron Therapeutics, Inc. and AP3-SD1 Campus Point LLC
2018-04-03	8-K	10.1	Waiver, dated March 28, 2018, between Heron Therapeutics, Inc. and Tang Capital Partners, LP
2017-08-09	10-Q	10.1	Executive Employment Agreement, dated April 24, 2017, by and between the Company and Robert E. Hoffman
2017-03-17	8-K	10.1	First Amendment to Lease dated March 15, 2017
2017-01-24	8-K	10.1	Waiver, dated January 18, 2017, between Heron Therapeutics, Inc. and Tang Capital Partners, LP
2016-12-23	10-K/A	10.36	Commercial Supply Agreement, dated December 8, 2015, by and between Heron Therapeutics, Inc. and SAFC, Inc.
2016-11-08	10-Q	10.3	Lease Agreement, dated October 18, 2016, by and between Heron Therapeutics, Inc. and AP3-SD1 Campus Point LLC
2016-11-08	10-Q	10.2	Subordinated Secured Promissory Note, dated August 5, 2016, by and between Heron Therapeutics, Inc. and Tang Capital Partners, LP and TC Management Services, LLC
2016-11-08	10-Q	10.1	Security Agreement, dated as of August 5, 2016, by and among Heron Therapeutics, Inc., Tang Capital Partners, LP and TC Management Services, LLC
2016-05-05	10-Q	10.1	Executive Employment Agreement, dated January 28, 2016, by and between Heron Therapeutics, Inc. and Kimberly Manhard
2016-04-15	8-K	10.1	Fourth Amendment to Lease, effective as of April 11, 2016, by and between the Company and Metropolitan Life Insurance Company
2016-02-19	10-K	10.36	Commercial Supply Agreement, dated December 8, 2015, by and between Heron Therapeutics, Inc. and ***.
2015-11-06	10-Q	10.1	Executive Employment Agreement, dated October 12, 2015, by and between Heron Therapeutics, Inc. and Neil Clendeninn
2015-05-29	8-K	10.1	SUSTOL® (granisetron, extended release) Injection Commercial Manufacturing Services Agreement – Finished Final Drug Product, dated May 27, 2015, by and between Heron Therapeutics, Inc. and Lifecore Biomedical, LLC
2015-05-08	10-Q	10.4	Amendment to Executive Employment Agreement, dated November 1, 2013, as amended on April 22, 2015, by and between Heron Therapeutics, Inc. and Paul Marshall
2015-05-08	10-Q	10.3	Amendment to Management Retention Agreement, dated October 23, 2013, as amended on April 22, 2015, by and between Heron Therapeutics, Inc. and Brian G. Drazba
2015-05-08	10-Q	10.2	Amendment to Executive Employment Agreement, dated May 1, 2013, as amended on April 22, 2015, by and between Heron Therapeutics, Inc. and Robert Rosen
2015-05-08	10-Q	10.1	Amendment to Executive Employment Agreement, dated May 1, 2013, as amended on April 22, 2015, by and between Heron Therapeutics, Inc. and Dr. Barry Quart
2014-03-07	10-K	10.AE	Offer Letter dated November 10, 2012 between the Company and Mark S. Gelder, M.D.
2014-03-07	10-K	10.AF	Offer Letter dated October 16, 2013 between the Company and Brian G. Drazba.
2014-03-07	10-K	10.AG	Management Retention Agreement as of October 23, 2013, by and between the Company and Brian G. Drazba.
2014-03-07	10-K	10.AH	Executive Employment Agreement, dated November 1, 2013, by and between the Company and Paul Marshall.
2013-08-08	10-Q	10.AL	– Form of Non-Qualified Stock Option Agreement.
2013-08-08	10-Q	10.AM	– Amendment to Management Retention Agreement, dated as of April 25, 2011, as amended May 29, 2013 (as amended, the “Retention Agreement”)
2013-05-10	10-Q	10.AI	– Executive
2013-05-10	10-Q	10.AJ	– Executive Employment
2013-05-10	10-Q	10.AK	– Executive Employment Agreement, dated May 1, 2013, by and between the Company and Stephen Davis.
2013-03-01	10-K	10.AG	Management Retention Agreement as of October 15, 2012 by and between the Company and Robert Rosen.
2013-03-01	10-K	10.AH	Management Retention Agreement as of December 3,2012, by and between the Company and Mark Gelder, M.D.
2012-07-25	8-K	10.2	REGISTRATION RIGHTS AGREEMENT
2012-07-25	8-K	10.1	SECURITIES PURCHASE AGREEMENT
2011-08-03	8-K	10.1	THIRD AMENDMENT TO LEASE
2011-06-30	8-K	10.2	AMENDMENT TO SENIOR SECURED CONVERTIBLE NOTE DUE 2021
2011-06-30	8-K	10.1	SECURITIES PURCHASE AGREEMENT
2011-04-28	8-K	10.6	MANAGEMENT RETENTION AGREEMENT, DATED AS OF APRIL 25, 2011 - MICHAEL A. ADAM
2011-04-28	8-K	10.5	MANAGEMENT RETENTION AGREEMENT, DATED AS OF APRIL 25, 2011 - JOHN B. WHELAN
2011-04-28	8-K	10.4	SECOND AMENDMENT TO LEASE
2011-04-28	8-K	10.3	SECURITY AGREEMENT
2011-04-28	8-K	10.2	FORM OF SENIOR SECURED CONVERTIBLE NOTE DUE 2021
2011-04-28	8-K	10.1	SECURITIES PURCHASE AGREEMENT
2010-06-01	8-K	10.1	SEPARATION AND RELEASE AGREEMENT
2010-05-17	10-Q	10.O	FORM OF 2007 DIRECTOR'S RESTRICTED STOCK AWARD AGREEMENT
2009-11-16	10-Q	10.1	DEVELOPMENT AND LICENSE AGREEMENT
2009-10-22	8-K	10.4	SECOND AMENDMENT
2009-10-22	8-K	10.3	WARRANT
2009-10-22	8-K	10.2	RIGHTS AGREEMENT
2009-10-22	8-K	10.1	PURCHASE AGREEMENT
2009-03-31	10-K	10.V	AMENDMENT TO EMPLOYMENT LETTER AGREEMENT WITH RONALD PRENTKI, PRESIDENT AND CEO
2009-03-31	10-K	10.W	AMENDMENT TO MANAGEMENT RETENTION AGREEMENT - DR. JOHN BARR
2009-03-31	10-K	10.X	EMPLOYMENT LETTER AGREEMENT WITH JOHN B. WHELAN, CFO

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Clene Inc. (CLNN)	United States	$0.054B	-1.99
Serina Therapeutics, Inc. (SER)	United States	$0.054B	-2.35
Annovis Bio, Inc. (ANVS)	United States	$0.056B	-1.58
Xilio Therapeutics, Inc. (XLO)	United States	$0.052B
NOMAD POWER SOLUTIONS, INC. (NMAD)	United States	$0.058B
Boundless Bio, Inc. (BOLD)	United States	$0.059B	-0.88
TALPHERA, INC. (TLPH)	United States	$0.060B
Elicio Therapeutics, Inc. (ELTX)	United States	$0.049B
CalciMedica, Inc. (CALC)	United States	$0.061B	-1.42
Lite Strategy, Inc. (LITS)	United States	$0.049B